Head-to-head evidence
MET-097i vs MET-233i
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: Amylin receptor · full Obesity pipeline
MET-097i
Developed by Pfizer
NCT06712836 · Phase 2 · completed
The study randomized 239 participants to MET097 or placebo and used quadruple masking of participants, care providers, investigators, and outcome assessors. Its primary endpoint was the clinical outcome of body-weight change at Week 28. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: January 2027 · NCT07508241 (registry estimate)
MET-233i
Developed by Pfizer
NCT07022977 · Phase 1 · completed
Participants were randomly assigned to MET233 or a matching placebo, with everyone blinded to the assignment, which is a sound safety-testing design. However, the trial's main measure was side-effect occurrence rather than weight loss, which was only a secondary measure, and results have not been posted yet.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: MET-097i's landscape · MET-233i's landscape